Compound Ion Salt, a Novel Low-Sodium Salt Substitute: From Animal Study to Community-Based Population Trial
Compound Ion Salt, a Novel Low-Sodium Salt Substitute: From Animal Study to Community-Based Population Trial
复制标题
DOI：
10.1038/ajh.2009.135
复制
发表时间：
2009-09-01
影响因子：
3.2
通讯作者：
Li, Yu-Ming
中科院分区：
文献类型：
--
作者：
Zhou, Xin;Liu, Jun-Xiang;Li, Yu-Ming
背景：限盐是高血压一级和二级预防的一种重要方法，但由于坚持程度不理想而受到影响。一项限盐研究在动物模型和社区人群中测试了低钠含量的复合离子盐（CISalt）的有效性和安全性。方法在第一部分中，8周龄雄性自发性高血压大鼠（SHRs）分别饲喂1% CISalt研究组和8%或1%正常盐（NSalt）对照组（n = 10），持续12周。每3周测量一次血压和尿电解质。12周后，测定大鼠心脏和肾脏胶原沉积、血浆和肾皮质血管紧张素II （Ang II）和一氧化氮（NO）水平。在第二部分中，在10个农村社区的248人（年龄0 = 65岁）中进行了一项单盲、随机、为期6个月的CISalt对照试验。血浆肾素活性和Ang II在基线和6个月时包括血液和尿液测量。结果与对照组相比，喂食ClSalt的动物血压尿蛋白排泄量降低，心脏和肾脏胶原蛋白减少。在人体研究中，6个月时，与对照组相比，平均收缩压（SBP）分别下降9.6 mm Hg（95%可信区间（CI）： 13.1 ~ 6.1, P < 0.001）和舒张压（DBP）分别下降5.3 mm Hg (95% CI: 7.9 ~ 2.6, P < 0.001)；尿钠排泄量减少67.4 mmol/24 h (95% CI: 84.8 ~ 50.0, P < 0.001)，血浆肾素活性略有增加0.19 ng/ml/h （95% CI: 0.04 ~ 0.33, P = 0.013）。无不良心血管事件报道。结论：在这些研究中，CISalt降低血压，并在高血压动物和人类中显示终器官保护作用。盐似乎是一种安全且可接受的降低血压的策略。Am J Hypertens 2009；中国高血压病杂志，2009 (3):344 - 344 (C)
BACKGROUND Salt restriction, an important approach for primary and secondary prevention of hypertension, is undermined by unsatisfactory adherence. A salt-restriction study tested the efficacy and safety of a compound ion salt (CISalt) with low sodium content in an animal model and in a community-based population.METHODS In part 1, 8-week-old male spontaneously hypertensive rats (SHRs) were fed 1% CISalt in the study group and 8% or 1% normal salt (NSalt) in controls (n = 10 each) for 12 weeks. Blood pressure (BP) and urinary electrolytes were measured every 3 weeks. After 12 weeks, Collagen deposition in the heart and kidney and the levels of angiotensin II (Ang II) and nitric oxide (NO) in plasma and renal cortex were measured. In part 2, a single-blind, randomized, 6-month controlled trial with CISalt was conducted in 248 persons (age >= 65 years) in 10 rural communities. Plasma renin activity and Ang II were included in blood and urinary measures at baseline and 6 months.RESULTS Reduced BP urinary protein excretion and reduced Collagen in the heart and kidneys were significantly different in animals fed ClSalt compared to controls. In human studies, at 6 months, mean systolic BP (SBP) was decreased by 9.6 mm Hg (95% confidence interval (CI): 13.1 to 6.1, P < 0.001) and diastolic BP (DBP) by 5.3 mm Hg (95% CI: 7.9 to 2.6, P < 0.001), respectively, compared to controls; urinary sodium excretion also decreased by 67.4 mmol/24 h (95% CI: 84.8 to 50.0, P < 0.001), and plasma renin activity was slightly increased by 0.19 ng/ml/h (95% CI: 0.04-0.33, P = 0.013). No adverse cardiovascular events were reported.CONCLUSIONS In these studies, CISalt lowered BP and showed end-organ protection in hypertensive animals and BP reduction in humans. ClSalt appears to be a safe and acceptable strategy to reduce BP. Am J Hypertens 2009; 22:934-942 (C) 2009 American Journal of Hypertension, Ltd.